Rotkreuzklinikum Muenchen gGmbH — Clinical Trial Site

43 Registered trials

19 Currently recruiting

Organisation

Rotkreuzklinikum Muenchen gGmbH

Location

Munich, Germany

Identifier

ORG-100045779

Address

Taxisstrasse 3, Neuhausen-Nymphenburg, 80637, Germany

Departments

#3153: Frauenklinik
2610: Gynäkologie,Brustzentrum
Frauenklinik
Gynaecology
Gynaekologie
Gynäkologie
Gynecologic Oncology and Minimally-invasive Surgery
Hämatologie/Onkologie
Hematology
III. Med. Abteilung Hämatologie und Onkologie
III. Medizinische Abteilung
III. Medizinische Abteilung - Hämatologie und Onkologie
Innere Medizin III
Innere Medizin III – Hämatologie und Onkologie
Innere Medizin III; Hämatologie und Onkologie
Interdisziplinäres Brustzentrum
Interdisziplinbäres Brustzentrum
Klinik für Hämatologie und Onkologie
Medical oncology
Oncology
Oncology Day Clinic and Study Center at the Women's Clinic in Taxisstraße / Rotkreuzklinikum Munich
Onkologische Tagesklinik der Frauenklinik
Rotkreuzkliniken München, Interdisziplinbäres Brustzentrum

Clinical trials at this site (43)

Search interface

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously U… Ended

2023-504194-21-00 PD-L1 Positive Metastatic Triple-Negative Breast Cancer 5 2022-09-13
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca… Ended

2023-509631-37-00 "Inoperable or Metastatic Hormone Receptor-Positive, HE 5 2022-01-18
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible fo… Ended

2024-516959-40-00 This trial evaluates the efficacy and safety of Mirvetu 4 2021-08-17
A study to investigate the efficacy and safety of trastuzumab deruxtecan in patients With or Without Brain Metastasis Who Have Previously-Tr… Ended

2024-510588-53-00 Treatment of patients with HER2-positive breast cancer 11 2021-06-10
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma. Ended

2024-514775-17-00 Malignant B-cell lymphoma 4 2021-02-10
KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA… Ended

2024-513252-15-00 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL 4 2021-01-28
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
Reduced intensity radio-chemotherapy for stage IIA/B seminoma Ended

2023-509663-24-00 Stage IIA/B seminoma 4 2020-08-20
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk… Ended

2024-515769-32-00 HR+/HER2- early breast cancer 5 2019-07-02
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel… Ended

2024-515783-31-00 Newly Diagnosed Multiple Myeloma 5 2018-08-24
EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) wit… Ended

2024-513509-30-00 Progressive or recurrent germ cell tumor (measurable or 5 2016-01-11
Safety, tolerability, and efficacy of ACOU085 for prevention of hearing loss in testicular cancer patients receiving cisplatin Ended

2023-503696-15-00 sensorineural hearing loss (SNHL) 4 2023-11-10
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13